MedPath

Evaluation of the evolution of patients with vitreous hemorrhage caused by proliferative diabetic retinopathy subjected to intravitreal injection of antivascular endothelial growth factor (bevacizumab)

Phase 3
Recruiting
Conditions
proliferative diabetic retinopathy
vitreous hemorrhage
Registration Number
ACTRN12618000697280
Lead Sponsor
Hospital Oftalmológico de Sorocaba
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath